BCL2L1 and B-cell chronic lymphocytic leukemia: Other B lymphomas with high BCL-2 that respond to venetoclax as a single agent include mantle cell lymphoma and, less frequently, follicular lymphoma, myeloma and some diffuse large B-cell lymphomas.91 Responses in FL and myeloma often required higher doses than in CLL, probably because MCL-1 and BCL-XL are more abundant than in CLL.92 Relapsed or refractory acute myeloid leukaemia (AML) has also shown modest single agent responsiveness (19%).93